Uncertainty and novel clinical trial designs in oncology – when should equipoise matter?

Sarah Heynemann, Wendy Lipworth, Sue-Anne McLachlan, Jennifer Philip, Tom John, Ian Kerridge · 2026

Read Uncertainty and novel clinical trial designs in oncology – when should equipoise matter? by Sarah Heynemann, Wendy Lipworth, Sue-Anne McLachlan, Jennifer Philip, Tom John, Ian Kerridge (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13624340.txt.

Description

Heynemann and five co-authors ask when fairness between treatment arms should still govern cancer trials, in this two thousand twenty-six ethics article. Equipoise, the honest uncertainty about which arm is better, is the classic moral license for randomizing patients.

Modern oncology increasingly uses designs that break the classic mold: seamless trials that flow from one phase to the next, adaptive trials that shift as data arrives, and long-running platform trials. The authors argue these designs strain equipoise as a useful moral tool, because risk and uncertainty change shape mid-trial. Equipoise still anchors ordinary trials, they say, but new designs need additional ethical instruments to judge the risks participants take on.

Catalog record

CREATORSarah Heynemann, Wendy Lipworth, Sue-Anne McLachlan, Jennifer Philip, Tom John, Ian Kerridge
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE44 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13624340

Browse the full library · About the Tower of Babel